Generation Bio to Present at the Canaccord Genuity 44th Annual Growth Conference
2024年8月6日 - 7:59PM
Generation Bio Co. (Nasdaq:GBIO) a biotechnology company
innovating genetic medicines for people living with rare and
prevalent diseases, announced that Geoff McDonough, M.D., president
and chief executive officer, will participate in a fireside chat at
the Canaccord Genuity 44th Annual Growth Conference on Tuesday,
August 13th, 2024 at 2:30 p.m. ET in Boston.
A live webcast of the presentation will be available on the
investor section of the company’s website
at investors.generationbio.com. A replay will be available
there for 30 days following the event.
About Generation Bio
Generation Bio is innovating non-viral genetic medicines to
provide durable and redosable treatments for hundreds of millions
of patients living with rare and prevalent diseases. The company is
developing two distinct and complementary platforms: a potent,
highly selective cell-targeted lipid nanoparticle (ctLNP) delivery
system and a novel immune-quiet DNA (iqDNA) cargo produced by a
scalable capsid-free manufacturing process that uses proprietary
cell-free rapid enzymatic synthesis (RES). With these platforms,
Generation Bio aims to develop the next wave of non-viral genetic
medicines to support its mission to extend the reach of genetic
medicine to more people living with more diseases, around the
world.
For more information, please
visit www.generationbio.com.
Investors and Media ContactMaren
KillackeyGeneration Biomkillackey@generationbio.com857-371-4638
Generation Bio (NASDAQ:GBIO)
過去 株価チャート
から 7 2024 まで 8 2024
Generation Bio (NASDAQ:GBIO)
過去 株価チャート
から 8 2023 まで 8 2024